Vardhanabhuti Saran, Taiwo Babafemi, Kuritzkes Daniel R, Eron Joseph J, Bosch Ronald J
Harvard School of Public Health, Boston, MA, USA.
Antivir Ther. 2015;20(1):73-6. doi: 10.3851/IMP2772. Epub 2014 Apr 4.
Persistent low-level viraemia (LLV) during the treatment of antiretroviral therapy (ART) is associated with emergent drug resistance mutation (DRM); however, insight into its driver is limited. The objectives were to study HIV-1 pol sequence evolution in subjects with persistent LLV and evaluate factors associated with sequence changes.
HIV-1 pol sequences from 54 treatment-naive subjects undergoing first-line lopinavir/ritonavir- or efavirenz-containing ART were obtained at pre-ART and end of LLV. HIV-1 sequence evolution was evaluated using phylogenetic analysis and Hamming distance calculation. DRMs were interpreted based on the International AIDS Society-USA 2011 update.
Subjects with new DRM during LLV had greater HIV-1 evolution across pol from the pre-ART to end of LLV compared with subjects without DRM. Evolution over non-DRM sites was similar between groups. Higher degree of genetic evolution was positively associated with higher HIV-1 RNA levels during LLV, both at DRM and non-DRM sites.
The magnitude of LLV was the primary driver of evolution rate at DRM as well as non-DRM sites. Higher viral load was associated with DRM emergence in these subjects. These findings provide insights that may be applicable to the management of patients with persistent LLV during ART.
抗逆转录病毒疗法(ART)治疗期间持续的低水平病毒血症(LLV)与新出现的耐药性突变(DRM)相关;然而,对其驱动因素的了解有限。目的是研究持续存在LLV的受试者中HIV-1 pol序列的演变,并评估与序列变化相关的因素。
从54名接受含洛匹那韦/利托那韦或依非韦伦的一线ART治疗的初治受试者中,在ART治疗前和LLV结束时获取HIV-1 pol序列。使用系统发育分析和汉明距离计算评估HIV-1序列的演变。根据美国国际艾滋病协会2011年更新版对DRM进行解读。
与无DRM的受试者相比,LLV期间出现新DRM的受试者从ART治疗前到LLV结束时,pol基因的HIV-1进化程度更高。两组间非DRM位点的进化情况相似。在DRM和非DRM位点,更高程度的基因进化与LLV期间更高的HIV-1 RNA水平呈正相关。
LLV的程度是DRM以及非DRM位点进化速率的主要驱动因素。在这些受试者中,更高的病毒载量与DRM的出现相关。这些发现为ART期间持续存在LLV的患者管理提供了可能适用的见解。